The Expression and Ovarian Steroid Regulation of Endometrial Micro-RNAs

T. Toloubeydokhti, Toloubeydokhti T, Tannaz Toloubeydokhti, Qun Pan, Pan Q, Xiaoping Luo, Luo X, Orhan Bükülmez, Orhan Bukulmez, Bukulmez O, Nasser Chegini, Chegini N
Reproductive sciences (Thousand Oaks, Calif.) · 2008 · vol. 15(10) , pp. 993–1001 · doi:10.1177/1933719108324132 · PMID:19088369 · PMC2729333 · W1566032609
article OA: green CC0 RETRACTED ⤵ 33 in-corpus citations
Retraction notice. Marked retracted by OpenAlex; see publisher for the formal retraction notice.
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-12 ⓘ

This study assessed the expression of specific miRNAs and their target genes (StAR, CYP19A1, COX-2) in endometrial tissues and cells, and examined how estradiol and progesterone affect their expression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

The paper examined expression of four microRNAs (miR-17-5p, miR-23a, miR-23b, and miR-542-3p) and predicted target genes, alongside steroidogenic acute regulatory protein, aromatase, and cyclooxygenase-2, in paired ectopic endometrium (ECE) and eutopic endometrium (EUE) compared with normal endometrium (NE). Using endometrial stromal and glandular epithelial cell models, the authors found that miR-23b and miR-542-3p were lower and miR-17-5p was higher in ECE and EUE versus NE, with these miRNA levels elevated and inversely correlated with target gene expression in ECE. They also reported differential regulation of miRNAs and genes by 17β-estradiol, medroxyprogesterone acetate, the estrogen receptor antagonist ICI-182780, and RU-486 in stromal and epithelial cells. The study’s caveat is that it includes limited miRNA targets and relies on predicted gene relationships rather than comprehensive validation. This paper is centrally about endometriosis — it analyzes altered microRNA expression in ectopic endometrium and links steroid regulation and miRNA–target gene stability to endometriosis pathogenesis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

MicroRNAs (miRNAs) which regulate gene expression stability displayed an aberrant expression profile in ectopic endometrium (ECE) as compared to eutopic (EUE) and normal endometrium (NE). We assessed the expression of miR-17-5p, miR-23a, miR-23b and miR-542-3p, their predicted target genes, steroidogenic acute regulatory protein, aromatase and cyclooxygenase-2, and influence of ovarian steroids on their expression in endometrial stromal (ESC) and glandular epithelial cells (GEC). The results indicated a lower expression of miR-23b and miR-542-3p and higher level of miR-17-5p in paired ECE and EUE as compared with NE. These levels were elevated and inversely correlated with the level of expression of their respective target genes in ECE. The expression of these miRNAs and genes was differentially regulated by 17beta- estradiol, medroxyprogesterone acetate, ICI-182780 and RU-486, or their respective combinations in ESC and GEC. We concluded that altered expression of specific miRNAs in ECE, affecting the stability of their target genes expression, has direct implications in pathogenesis of endometriosis.
Full text 19,634 characters · extracted from pmc-nxml · 5 sections · click to expand

Intro

We have recently reported the expression profile of a group of micro-RNAs (miRNAs) in the endometrium of women with and without endometriosis (EN) and endometrial cells isolated from these tissues. Among the miRNAs identified as differentially expressed in the endometrium of women with and without EN, include miR-17-5p, miR-23a, miR-23b, miR-542-3p, miR-18a, miR-206, miR-181a, and miR-142-5p. 1 These miRNAs are predicted to target the expression of many genes, including steroidogenic acute regulatory protein (StAR), CYP19A1, cyclooxygenase 2 (COX-2), estrogen receptors (ERα and ERβ), and progesterone receptors (PRs), respectively. The expression of these genes has been well documented in human endometrium with their altered expression in eutopic (EU) and ectopic (EC) endometrium of women with EN. 2 , 3 More specifically, the EC endometrium has been reported to express different levels of ERα, ERβ, and PRs as compared to the endometrium of women without EN 2 , 3 with EC tissue reported to only express PR-A.4 We have also identified a lower level of miR-18a, miR-206, miR-181a, and miR-142-5p expression in EC endometrium as compared to paired EU and endometrium of women without EN. 1 Local estrogen biosynthesis and deficient metabolism by the endometriotic cells have also been considered to influence the growth of the EC endometrium. 4 – 7 Estrogen biosynthesis is regulated by aromatase (CYP19A1), steroid sulfatase, and estrogen sulfotransferase. The aromatase catalyzes the conversion of androstenedione to testosterone, which can be directly aromatized to 17β-estradiol (E 2 ). Aromatase is expressed in a number of cells and tissues, and in the endometrium it is expressed by the stromal cells with elevated expression in EC endometrium. 5 , 8 – 10 The expression of CYP19A1 in endometrial stromal cells (ESCs) is regulated by StAR, which has a rate-limiting regulatory function on steroid production in a number of cell types. 7 , 11 The expression of StAR is regulated by many factors, including luteinizing hormone (LH) receptor-activation of cyclic adenosine monophosphate (cAMP) and several cytokines and growth factors that are expressed by the endometriotic tissues. 11 – 18 Several products of COX-2, the rate-limiting enzyme involved in the conversion of arachidonic acid to prostanoids, specifically prostaglandin (PG) E 2 , have been shown to influence hormone-stimulated steroidogenesis and CYP19A1 and StAR expression. 19 As such, products of COX-2 pathway either directly or through regulation of CYP19A1 and StAR could influence the growth of EC endometrial implants. Gene expression profiling has provided considerable evidence in support of altered expression of a number of genes in various endometrial disorders, including EN as compared to normal endometrium. 20 – 25 Accumulated evidence also suggests that miRNAs play a key regulatory function in gene expression stability through their regression and possibly degradation. 26 – 28 Several hundred miRNAs have been identified and/or predicted in many cells and tissues from different species, and in humans, it is estimated that the expression of 30% of the genes are potential target of their actions. 29 – 32 As such miRNAs, through gene expression stability, play a central role in various cellular activities, including developmental processes, cell growth, differentiation and apoptosis, cell–cell communication, inflammatory and immune responses. 33 – 37 Many of these processes are an integrated part of normal endometrial cellular activities during the menstrual cycle, and their alterations account for pathogenesis of EN. The aims of this study included the assessment of the expression of miR-17-5p, miR-23a, miR-23b, miR-542-3p and possible correlation with the expression of their predicted target genes, StAR, CYP19A1, and COX-2, respectively, in the endometrium of women without EN, and paired EU and EC endometrium samples of women with EN. We then determined the expression of these miRNAs and genes in isolated ESCs and glandular epithelial cells (GECs) and studied whether E 2 and medroxyprogesterone acetate (MPA), as well as their respective antagonists ICI-182780 and RU-486, altered their expression.

Methods

All the in vitro experiments were performed at least 3 times in duplicate using independent cell cultures. Where appropriate, the results are expressed as mean ± standard error (SEM) and statistically analyzed using either a 2-tailed Student t test for two group comparisons or ANOVA with post hoc Tukey’s test for multiple comparisons, with P < .05 considered significant.

Results

Using real-time PCR, we assessed the expressions of miR-17-5p, miR-23a, miR-23b, and miR-542-3p, as well as StAR, CYP19A1, and COX-2 in EN and paired EU and EC. Based on the CT values, these tissues expressed higher levels of miR-23b followed by miR-23a, miR-17-5p, and miR-542-3p. They also expressed higher levels of StAR, followed by COX-2 and CYP19A1 with relative mean expression negatively correlating with their corresponding miRNAs. For comparative analysis, the expression values were normalized and the mean expression for each miRNA and mRNA was set as 1 in EN. The analysis indicated that miR-17-5p, miR-23a, miR-23b, and miR-542-3p are expressed at significantly elevated levels in EU and EC, with a lower expression of miR-23b in EC as compared to EU and EN ( Figure 1 , P < .05). Similar analysis indicated a higher level of CYP19A1, StAR, and COX-2 expression in EC as compared to EU and EN, and significantly higher levels in EU as compared to EN ( Figure 1 ; P < .05). The ESCs and GECs isolated from EN also expressed miR-17-5p, miR-23a, miR-23b, and miR-542-3p as well as CYP19A1, StAR, and COX-2. The level of their expression in ESC and GEC was relatively lower as compared to EN with the exception of COX-2, and lower in GEC as compared to ESC (data not shown). Treatment of ESC and GEC with E 2 (10 −8 M) and MPA (10 −8 M) differentially regulated the expression of miR-17-5p, miR-23a, miR-23b, and miR-542-3p in cell-dependent and hormone-dependent manners ( Figures 2 and 3 ). E 2 inhibited the expression of miR-23a and miR-23b in ESC and miR-23a and miR-542-3p in GEC, while increasing the expression of miR-17-5p and miR-542-3p in ESC, and miR-17-5p, miR-23b, and miR-142-5p in GEC as compared to untreated controls ( Figures 2 and 3 ; P < .05). MPA (10 −8 M) also inhibited the expression of miR-23a in ESC and miR-542-3p in GEC, while increasing the expression of miR-17-5p and miR-542-3p in ESC and other miRNAs in GEC as compared to untreated controls ( Figures 2 and 3 ; P < .05). Treatments of ESC and GEC with ICI-182780 and RU-486 (10 −6 M) either inhibited or stimulated the expression of these miRNAs, and co-treatment with E 2 or MPA respectively, resulted in an antagonistic or additive effect induced by E 2 and MPA, or were without any significant effects ( Figures 2 and 3 ; P < .05). The expression of StAR, CYP19A1, and COX-2 by ESC and GEC was also altered following treatments with E 2 , MP A, ICI-182780, and RU-486. The expression of StAR in ESC did not significantly change following treatments with E 2 , ICI-182780, or E 2 + ICI-182780, increased by MPA (not significant) while inhibited by RU-486 ( Figure 2 ; P < .05). The expression of StAR in GEC was increased following treatments with E 2 and MPA, which was reduced to control levels following E 2 + ICI-182780 treatment ( Figure 3 ; P < .05). The expression of COX-2 was significantly increased by E 2 and MPA, and inhibited reaching control levels following co-treatment with ICI-182780 and RU-486, respectively ( Figures 2 and 3 ; P < .05). The expression of CYP19A1 was significantly increased by E 2 in GEC and by MPA in ESC and GEC, and inhibited/reduced by ICI-182780 and RU-486, and co-treatments with E 2 and MPA, respectively, in ESC ( Figures 2 and 3 ; P < .05).

Discussion

We have recently reported the expression profile of a number of miRNAs in endometrium of women with and without EN and in isolated endometrial GECs and stromal cells. 1 Because of the importance of steroid receptors in the pathogenesis of EN, we selected and validated the expression of several of these miRNAs (miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a, and miR-142-5p), which are predicted to target many genes, including TGF-β, ERα, ERβ, and PR, respectively. 1 Local estrogen biosynthesis has also been considered to influence the growth of EC endometrium with StAR, CYP19A1, and COX-2 playing a central role in this process. 5 In the present study, we demonstrated that the endometrium of women with and without EN and EC endometrium express miR-17-5p (StAR), miR-23a, miR-23b (CYP19A1), and miR-542-3p (COX-2). Based on their computed tomography (CT) values, miR-23b expressed at higher levels (lowest CT value) followed by miR-23a, miR-17-5p, and miR-542-3p, and there was higher StAR expression followed by COX-2 and CYP19A1. Comparative analysis of the relative mean expression values of these miRNAs and genes in paired EU and EC endometrium further indicated an overall upregulation of their expression as compared to EN. Since miRNAs are considered to repress or degrade the expression of their target genes, we found such an inverse correlation between the expression of miR-23a, miR-23b, and miR542-3p and CYP19A1 and COX-2 expression, respectively, but not with miR17-5p and StAR expression. As such, a lower expression of miR23a/miR23b was correlated with higher CYP19A1 expression and miR-542-3p with COX-2 expression in EC as compared to EN and EU. In addition to posttranscriptional repression, a recent report proposed that miRNAs may also result in translational activation of target genes. 40 In this respect, detailed investigations are required to establish if such a regulatory interaction between miR-23, miR-17-5p, and miR-542-3p as well as other miRNAs results in alteration of their target genes in EN, EU, and EC. Since several endometrial cell types contribute to the overall expression of these miRNAs, we isolated the ESCs and GECs addressing their cellular expression and examined their regulation by the ovarian steroids. Although a considerable variation was observed between the level of expression of miR-17-5p, miR-23a, miR-23b, and miR-542-3p in EN and their isolated stromal cells and GECs, they were expressed in lower levels in ESC and GEC. The level of expression of these miRNAs was higher in ESC and compared to GEC, suggesting differential regulation of their target genes in a cell-specific manner. These cells expressed relatively similar levels of COX-2, but expressed lower levels of StAR and CYP19A1 as compared to EN. Variations in the expression of miRNAs have been observed in other tissues and their isolated cells and loss of cell–cell interactions and culture conditions are considered as contributing factors for the difference. 41 – 46 With respect to the expression of CYP19A1 and StAR, stromal, but not epithelial cells isolated from ovarian endometriotic cysts, stromal cells of extra-ovarian and ovarian endometriotic tissues have been shown to express StAR and aromatase, and their enzyme activities. 5 Cyclooxygenase 2 is also expressed by the endometrial tissues and cells, and PGE 2 or a cAMP analogue has been shown to induce StAR and aromatase expression and activity in the endometriotic stromal cells. 5 We also found an elevated expression of CYP19A1, StAR, and COX-2 in EC as compared to EU and EN; however, their expression in EN compared to EU contrasted from previously reported studies. 5 , 8 , 10 , 11 , 18 , 47 , 48 The most likely explanation for the difference could be the method of detection and primers used in these as compared to our study. 48 Whether the endometrial expression of StAR, CYP19A1, and COX-2 is directly targeted by miR-17-5p, miR-23a, miR-23b, and miR-542-3p is yet to be established, since a simple inverse correlation might not explain the complex regulatory interactions that occur between miRNAs and their target genes expression. Additionally, it has been predicted that several miRNAs can regulate the expression of one gene, or one miRNA may regulate the expression of many genes, implying that other miRNAs may also regulate the expression of StAR, CYP19A1, and COX-2. The results from the ovarian steroid actions on the expression of miR-17-5p, miR-23a, miR-23b, and miR-542-3p in the endometrial cells, and their alteration following treatments with ICI-182780 and RU-486, with both antagonistic and additive effects when used with E 2 and MPA, respectively also support our recent report with ovarian steroid regulation of miR-20, miR-21, and miR-26 expression in these cells. 1 Although we observed a wide variation in the ovarian steroid actions in combination with ICI-182780 and RU-486 on the expression of these miRNAs and genes, their regulatory actions occurred in cell-specific and hormone-specific manners, or ICI-182780 and RU-486 in occasions did not have the expected antagonistic effects. We are unaware of other studies on the effect of ICI-182780 and RU-486 on the expression of miRNAs for comparative analysis; however, other studies have reported agonistic and antagonistic or lack of effect of ICI-182780 and RU-486 on gene expression and other cellular activities. 49 – 55 Additionally, CYP19A1 expression has been reported not to change in response to E 2 treatment in leiomyoma smooth muscle cells, but was altered in response to GnRHa and danazol therapy in EU, adenomyosis, and leiomyomas. 56 , 57 In mouse leydig cells, MA-10, progesterone in a dose-dependent manner has also been reported to increase StAR expression, without significant changes following treatments with other steroids, including dexamethasone, estradiol, testosterone, and dihydrotestosterone. 58 Interestingly, RU-486, which acts as a potent antagonist of progesterone and glucocorticoid had a stimulatory effect, while dexamethasone inhibited StAR expression in MA-10 cells. 58 Progesterone, induced by LH and PGE 2 has also been found to increase StAR, 3β honestly significant differences, 58 and cytochrome P450scc gene expression in bovine luteal cells. 59 The results of our study suggest that an aberrant expression of miRNAs may contribute toward the pathogenesis of EN by targeting the stability of specific genes whose products are known to influence endometriotic cellular activities. In this respect, aberrant expression of several miRNAs, including miR-17-5p, miR-23, and miR-542-3p has been associated with a number of pathological disorders, specifically cancers. 60 In breast cancer cell lines with low levels of miR-17-5p expression, gain of function resulted in decreased ER-dependent and ER-independent gene expression, cell proliferation, and anchorage-independent growth. 61 Because miRNAs have a broad range of targets with an estimate of regulating the stability of at least 30% of genes 62 any change in the endometrial expression of a given miRNA could have a significant impact on the expression of many genes. As such our study provides further evidence that the endometrial expression of specific miRNAs, their altered expression in EC endometrium, and differential regulation by ovarian steroids in cultured endometrial cells may target the stability of StAR, CYP19A1, and COX-2. However, our study is limited to a degree of correlation between the expression of miR-17-5p, miR-23, and miR-542-3p and StAR, CYP19A1, and COX-2, respectively in the EU and EC endometrium, and detailed investigation is necessary to identify the specific genes targeted by these miRNAs allowing association of their biological function with pathogenesis of EN.

Materials|Methods

All the materials for isolation and culture of endometrial cells were purchased from commercial sources as previously described.38 MirVana RNA isolation and enrichment kits and real-time polymerase chain reaction (PCR) reagents were purchased from Ambion (Austin, Tex) and Applied Biosystem (Foster City, Calif), respectively. 17β-estradiol (E 2 ), MPA, and RU-486 were purchased from Sigma-Aldrich (St. Louis, Mo) and ICI-182780 was purchased from Tocris Cookson, Inc (Ballwin, Mo). Charcoal-stripped fetal calf serum was purchased from Hyclone (Logan, Utah). A total of 19 endometrial tissues consisting of EU (n = 5), EC (n = 9; five paired), and EN (n = 5) were obtained from premenopausal women who were scheduled to undergo hysterectomy for indications related to EN or symptomatic leiomyomas, respectively. The patients were not taking any medications, including hormonal therapy, for the pervious 3 months prior to surgery with their age ranging from 27 to 39 years (median = 32). Based on their last menstrual period and endometrial histology, the tissues were from early-mid secretory phase of the menstrual cycle. The EN was identified as stage III according to revised American Society for Reproductive Medicine (ASRM) staging. The tissues were collected at the University of Florida affiliated Shands Hospital with prior approval from the Institutional Review Board. Immediately after collection, portions of tissues were snapped frozen and kept in liquid nitrogen for further analysis, or used for cell isolation and culturing. The ESCs and GECs were isolated from a small portion of endometrial tissues and cultured in Dulbecco’s modified Eagle’s medium/Hams F12 supplemented with antimycotic/antibiotics and 10% fetal bovine serum at 37°C in a humidified 5% C0 2 incubator until reaching confluence. Prior to use, the purity of the cell cultures was determined using antibodies to vimentin and cytokeratin as previously described. 38 To determine whether ovarian steroids regulate the expression of miRNAs, ESCs and GECs (10 6 /well) were seeded in 6-well culture dishes and incubated for 48 hours as described above. The cells were made quiescent under serum-free condition for 24 hours and then treated with E 2 (10 −8 M), MPA (10 −8 M), ICI-182780 (10 − 6 M), RU-486 (10 −6 M), E 2 + ICI, or MPA + RU486 for 6 hours added to phenol red-free medium containing 2% charcoal-stripped fetal bovine serum (FBS) as previously described. 39 Total RNA was isolated from these tissues and cells using mirVana miRNA isolation Kit according to manufacturer’s instructions and their quality and yield were analyzed using Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, Calif). TaqMan real-time PCR was used to assess the expression of miR-17-5p, miR-23a, miR-23b, and miR-542-3p and their predicted target genes, StAR, CYP19A1, COX-2 messenger RNA (mRNA), respectively (Sanger miRBase database ( http://microrna.sanger.ac.uk/sequences ). Briefly, 10 ng of total RNA was reverse transcribed to complementary DNA (cDNA) with specific stem-loop primers for each miRNA or optimized concentration of FAM-labeled probe and forward and reverse primers for StAR, CYP19A1, and COX-2 selected from Assay on Demand (Applied Biosystems, Calif). Real-time PCR was carried out using Applied Biosystems 7300 Fast Real-time PCR System and Taqman Universal PCR Master Mix at 95°C for 10 minutes, at 95°C for 15 seconds, and 60°C for 1 minute for 40 cycles. The relative level of miRNAs and mRNAs expression was determined using the comparative method and Sequence Detection System 1.91 software following normalization of expression values to U6 and 18S ribosomal RNA (rRNA) expression, respectively. The values were converted into fold change based on a doubling of the PCR product in each PCR cycle, according to the manufacturer’s guidelines as previously described. 1

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometrium Gene Expression Regulation Gonadal Steroid Hormones MicroRNAs Ovary Adult Cells, Cultured Endometriosis Endometriosis Endometriosis Endometrium Endometrium Female Gene Expression Regulation Gene Expression Regulation Gonadal Steroid Hormones Gonadal Steroid Hormones Gonadal Steroid Hormones Humans MicroRNAs

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (62)

Cited by (33)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:18.065553+00:00
License: CC0 · commercial use OK